Dr Amna Sheri

Dr Amna Sheri

Dr Amna Sheri Consultant Medical
Oncologist | MBBS, MRCP, MD(Res)

Primary
Specialty: Medical Oncology

Sub-Specialties:
Breast Cancer (Early, Advanced, Young Women, Pregnancy-Associated) | Melanoma |
Immunotherapy & Biomarker-Driven Targeted Therapies

Affiliations:
HCA Healthcare UK (LOC Harley Street, The Harley Street Clinic, The Wellington
Hospital) | The London Clinic, Royal Free Hospital.

Summary

Dr Amna Sheri is a Consultant Medical Oncologist
specializing in precision systemic therapies for breast cancer and melanoma.
Utilizing advanced biomarker analysis, she designs highly personalized
treatment pathways incorporating targeted biologicals, antibody-drug conjugates
(ADCs), immunotherapies, and cutting-edge clinical trials. Her practice
balances leading-edge scientific precision with empathetic, holistic patient
care.

Clinical
Excellence & Background

· Specialist Training: Graduated from Imperial College
London (2004); completed higher specialist training in medical oncology at the
Royal Marsden Hospital.

· Research Doctorate: Awarded an MD(Res) by the
Institute of Cancer Research (ICR) for research focused on predicting outcomes
following pre-surgery (neoadjuvant) therapy.

· Consultant Experience: Appointed Consultant Medical
Oncologist at the Royal Free London NHS Foundation Trust in 2015.

Key Areas
of Expertise

· Biomarker-Driven & Pre-Surgery (Neoadjuvant) Care:
Advanced molecular profiling to tailor pre- and post-surgery therapies,
optimizing tumour shrinkage while minimizing unnecessary side effects.

· Clinical Trials & Research Integration: Directly connects patients to emerging drug developments and clinical trials (ADCs, AKT inhibitors, CDK4/6 therapies) and academic research (ctDNA liquid biopsies for early recurrence tracking, Immunotherapy toxicity).

· Immunotherapy Toxicity Leadership: Leads a specialized
Multidisciplinary Team (MDT) alongside organ specialists (gastroenterology,
endocrinology, rheumatology) to proactively manage and minimize treatment side
effects. Support for late effects from treatment.

· Complex & Young Women’s Breast Cancer: Tailored, compassionate treatment plans for young women and pregnancy-associated cases,
balancing aggressive oncology strategies with fertility preservation, bone health and
long-term quality of life.

Treatments
& Modalities Offered

· Systemic Therapies: Chemotherapy, targeted biologicals, and personalized endocrine/hormone and targeted regimens, antibody drug conjugates.

· Immunotherapies: Modern checkpoint inhibitors and Bispecifc antibodies tailored
for breast cancer and melanoma.

· Precision Second Opinions: In-depth review of
biomarker testing, ctDNA interpretation, and personalized strategy design.